Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma

Similar Items

• EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
  od: Jo, Ukhyun, i dr.
  Izdano: (2014)
• Amelioration of Hypercholesterolemia by an EGFR Tyrosine Kinase Inhibitor in Mice with Liver-Specific Knockout of Mig-6
  od: Lee, Jun Choul, i dr.
  Izdano: (2014)
• EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
  od: Yang, Jiyoul, i dr.
  Izdano: (2018)
• Discovery and Evaluation of Polymorphisms in the AKT2 and AKT3 Promoter Regions for Risk of Korean Lung Cancer
  od: Sung, Jae Sook, i dr.
  Izdano: (2012)
• Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
  od: Park, Ha Young, i dr.
  Izdano: (2016)